Fluidigm to develop and supply a custom high-throughput prep system for HLA typing
3 May 2013 | By kdm communications limited
The new system will help the DKMS accelerate...
List view / Grid view
News
Bristol-Myers Squibb receives US FDA sNDA approval for use of SUSTIVA® (efavirenz)
3 May 2013 | By Bristol-Myers Squibb Company
The U.S. FDA has approved a sNDA for SUSTIVA® (efavirenz)...
Sanofi appoints two new Members to the Executive Committee to lead the new Commercial Organization
2 May 2013 | By Sanofi
A new commercial organization to better align with its business priorities...
Gilead reports interim data from Phase 2 LONESTAR study
2 May 2013 | By Gilead Sciences
Gilead Sciences announced plans to initiate a third Phase 3 clinical trial...
Bulgin’s Buccaneer® connectors now rated to IP69K
1 May 2013 | By kdm communications limited
The Buccaneer range of advanced waterproof power and data connectors has been independently rated to IP69K – DIN 40050-9
Merck announces new $15 billion share repurchase program
1 May 2013 | By Merck
Merck's board of directors has authorized additional purchases of up to $15 billion of Merck’s common stock for its treasury.
FDA approves ACTEMRA for children living with a rare form of arthritis
30 April 2013 | By Roche
Roche announced that the U.S. FDA has approved ACTEMRA...
Teva expands management team
29 April 2013 | By TEVA
Teva appoints Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy Officer...
Merck & Co., Inc. and Pfizer enter worldwide collaboration agreement
29 April 2013 | By Merck
Agreement to develop and commercialize Ertugliflozin, an investigational medicine for type 2 diabetes...
GlaxoSmithKline and Impax Pharmaceuticals terminate their collaboration on IPX066
29 April 2013 | By GlaxoSmithKline
GSK and Impax Pharmaceuticals announced that they are terminating their collaboration...
Gilead receives Complete Response Letters from U.S. FDA for Elvitegravir and Cobicistat
29 April 2013 | By Gilead Sciences
FDA states that it cannot approve the applications in their current forms...
GSK announces regulatory submission for umeclidinium monotherapy in European Union
29 April 2013 | By GlaxoSmithKline
UMEC is an investigational bronchodilator molecule...
Pfizer presents Phase 3 safety and immunogenicity data on Prevenar 13 in adults aged 18 to 49 years
28 April 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
Positive CHMP opinion for XTANDI(TM) (enzalutamide) in advanced prostate cancer(1)
26 April 2013 | By Red Consultancy
Enzalutamide recommended for approval in the European Union (EU)...
Perosphere and Daiichi Sankyo enter into a clinical trial agreement
26 April 2013 | By Daiichi Sankyo
Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study...
